文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

托珠单抗用于COVID-19住院患者(RECOVERY):一项随机、对照、开放标签、平台试验

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
PubMed 文献 · Lancet · 2021-01-01
一句话结论对缺氧且全身炎症(CRP≥75 mg/L)的COVID-19住院成人,托珠单抗降低28天死亡率(31% vs 35%,率比0·85),获益独立于呼吸支持且在全身糖皮质激素基础上叠加。

RECOVERY平台试验纳入4116例住院COVID-19成人,均存在缺氧(吸空气氧饱和度<92%或需氧疗)且CRP≥75 mg/L,1:1随机接受常规治疗或常规治疗加托珠单抗400–800 mg(按体重)静脉给药,未改善者12–24 h后可给第二剂。28天死亡率托珠单抗组31%(621/2022)vs 常规治疗组35%(729/2094),率比0·85(95%CI 0·76–0·94;p=0·0028)。托珠单抗组28天内出院率更高(57% vs 50%;率比1·22;95%CI 1·12–1·33;p<0·0001),基线未接受有创机械通气者达到有创机械通气或死亡复合终点更少(35% vs 42%;风险比0·84;95%CI 0·77–0·92;p<0·0001)。所有预设亚组结果一致,包括接受全身糖皮质激素者。

要点

  • 纳入标准:住院COVID-19成人,吸空气氧饱和度<92%或需氧疗,且CRP≥75 mg/L。
  • 托珠单抗400–800 mg(按体重)静脉给药,12–24 h后病情未改善可给第二剂。
  • 28天死亡率托珠单抗组31%(621/2022)vs 常规治疗组35%(729/2094),率比0·85(95%CI 0·76–0·94;p=0·0028)。
  • 28天内出院率57% vs 50%(率比1·22;95%CI 1·12–1·33;p<0·0001)。
  • 基线未接受有创机械通气者,有创机械通气或死亡复合终点35% vs 42%(风险比0·84;95%CI 0·77–0·92;p<0·0001)。

适用人群与场景

  • 在英国住院的COVID-19成人,存在缺氧(吸空气氧饱和度<92%或需要氧疗)且CRP≥75 mg/L。
  • 4116例纳入托珠单抗评估,其中3385例(82%)同时接受全身糖皮质激素。

诊断标准与关键阈值

  • 缺氧:吸空气氧饱和度<92%或需要氧疗;全身炎症:C反应蛋白≥75 mg/L。

处置流程与药物剂量

  • 常规标准治疗加托珠单抗400–800 mg(按体重)静脉给药。
  • 若12–24 h后病情未改善,可给第二剂托珠单抗。
  • 对照组仅接受常规标准治疗。

研究设计与关键结果

  • 随机、对照、开放标签、平台试验(RECOVERY),纳入4116例住院COVID-19成人,1:1随机接受常规治疗或常规治疗加托珠单抗。
  • 28天死亡率:托珠单抗组31%(621/2022)vs 常规治疗组35%(729/2094),率比0·85(95%CI 0·76–0·94;p=0·0028)。
  • 28天内出院:托珠单抗组57% vs 常规治疗组50%,率比1·22(95%CI 1·12–1·33;p<0·0001)。
  • 基线未接受有创机械通气者,有创机械通气或死亡复合终点:托珠单抗组35% vs 常规治疗组42%,风险比0·84(95%CI 0·77–0·92;p<0·0001)。
  • 所有预设亚组结果一致,包括接受全身糖皮质激素者。

证据类型、等级与局限

  • 证据类型:随机、对照、开放标签、平台试验。
  • 试验注册:ISRCTN 50189673;ClinicalTrials.gov NCT04381936。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对住院COVID-19成人,若存在缺氧(吸空气氧饱和度<92%或需氧疗)且CRP≥75 mg/L,可在常规治疗基础上加用托珠单抗400–800 mg(按体重)静脉给药,12–24 h后病情未改善可给第二剂。
  • 获益可见于不同呼吸支持程度的患者,且在全身糖皮质激素治疗基础上额外获得。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation.

METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg-800 mg (depending on weight) given intravenously. A second dose could be given 12-24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936).

FINDINGS: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76-0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12-1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77-0·92; p<0·0001).

INTERPRETATION: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids.

FUNDING: UK Research and Innovation (Medical Research Council) and National Institute of Health Research.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021. PMID: 33933206. doi:10.1016/S0140-6736(21)00676-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。